The cancer immunotherapy market is primed for growth, with Immune Checkpoint Inhibitors, otherwise known as Immune Checkpoint Modulators, representing one of the area’s newest and most promising treatments.
This buzz of attention has propelled the R&D race in the immune checkpoint modulator arena, which boasts an optimistic pipeline of therapies with all eyes set on obtaining blockbuster status.
Pharma IQ presents this immune checkpoint modulator venture map, providing an overview of various companies developing products in the space and the cancers of focus. In cases where information could not be gathered on a modulator’s specific cancer of focus, the term ‘variety of tumors’ was chosen.
Download PDF Attachment